Comparison of auranofin, methotreaxate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial

Arthritis & Rheumatism

Volumn 35, Issue 3, 1992, Pages 259-269

  Williams, H James ^a   Ward, John R ^a   Reading, James C ^a   Brooks, Raye H ^a,b   Clegg, Daniel O ^a   Skosey, John L ^a,c   Weisman, Michael H ^a,d   Willkens, Robert F ^a,e   Singer, Joyce Z ^a,f   Alarcón, Graciela S ^a,g   Field, Elizabeth H ^a,h   Clements, Philip J ^a,i   Russell, I Jon ^a,j   Hochman, Rodney F ^a,k   Boumpas, Dimitrios T ^a,l   Marble, Dwight A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

^g University of Alabama at Birmingham   (United States)

^h UNIVERSITY OF IOWA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^k GUTHRIE RESEARCH INSTITUTE   (United States)

^l NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; METHOTREXATE;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL TOXICITY; HUMAN; JOINT MOBILITY; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ARTHRITIS, RHEUMATOID; AURANOFIN; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMAN; LEUKOPENIA; METHOTREXATE; MIDDLE AGE; SUPPORT, U.S. GOV'T, P.H.S.; THROMBOCYTOPENIA;

EID: 0026579862     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780350304     Document Type: Article

References (52)

1. Long‐term outcome of treating rheumatoid arthritis: results after 20 years
2. Rheumatoid arthritis: disappointing long‐term outcomes despite successful short‐term clinical trials
3. Does drug therapy slow radiographic deterioration in rheumatoid arthritis
4. Does aggressive therapy of RA affect outcome
5. Intractable rheumatoid arthritis: treatment with combined cyclophosphamide, azathioprine, and hydroxychloroquine
6. Remodeling the pyramid: a concept whose time has come
7. Gold therapy in rheumatoid arthritis: report of a multi‐centre controlled trial
8. A controlled trial of gold salt therapy in rheumatoid arthritis
9. Gold salts in the treatment of rheumatoid arthritis: a double‐blind study
10. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial
11. Complications of chyrostherapy: a review of recent studies
12. Auranofin: a unique oral chrysotherapeutic agent
13. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy
14. Methotrexate in Reiter's disease
15. Immunosuppressive effects of cytosine arabinoside and methotrexate in man
16. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial
17. Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized, double‐blind study
18. Efficacy of lowdose methotrexate in rheumatoid arthritis
19. Psoriasis‐liver‐methotrexate interactions
20. Liver biopsies from psoriatics related to methotrexate therapy. I. Findings in 123 consecutive non‐methotrexate treated patients
21. Methotrexate for psoriasis: a new therapeutic schedule
22. 1958 revision of diagnostic criteria for rheumatoid arthritis
23. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)
24. Therapeutic criteria in rheumatoid arthritis
25. A seven‐day variability study of 499 patients with peripheral rheumatoid arthritis
26. Preliminary criteria for clinical remission in rheumatoid arthritis
27. 2
28. Uses and abuses of analysis of covariance in clinical trials
29. Methotrexate and placebo therapy in rheumatoid arthritis
30. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine: a follow‐up study
31. The combination of methotrexate and azathioprine for resistant rheumatoid arthritis (abstract)
32. Improving the response to gold or d‐penicillamine by addition of sulphasalazine: a pilot study in 25 patients with rheumatoid arthritis
33. Sulphasalazine in rheumatoid arthritis: combination therapy with d‐penicillamine or sodium aurothiomalate
34. The combined use of oral methotrexate and intramuscular gold in rheumatoid arthritis (abstract)
35. Combination methotrexate and sulfasalazine in the management of rheumatoid arthritis: case observations
36. Combined therapy of rheumatoid arthritis with gold and chloroquine
37. A combination of d‐penicillamine and hydroxychloroquine for the treatment of rheumatoid arthritis (abstract)
38. Combined disease‐modifying chemotherapy for intractable rheumatoid arthritis
39. Low‐dose cytotoxic drug combination therapy in intractable rheumatoid arthritis (abstract)
40. Low‐dose cytotoxic drug combination therapy in intractable rheumatoid arthritis: two years later (abstract)
41. Sulphasalazine alone or in combination with d‐penicillamine in rheumatoid arthritis
42. Combined suppressive drug treatment in severe refractory rheumatoid disease: an analysis of the relative effects of parenteral methylprednisolone, cyclophosphamide, and sodium aurothiomalate
43. Combined d‐penicillamine and chloroquine treatment of rheumatoid arthritis: a comparative study
44. Controlled trial of hydroxychloroquine and D‐penicillamine singly and in combination in the treatment of rheumatoid arthritis
45. Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo‐controlled study
46. Double‐blind study comparing auranofin and hydroxychloroquine alone or in combination in rheumatoid arthritis (abstract)
47. The use of combinations of disease modifying antirheumatic agents in rheumatoid arthritis
48. Long acting drug combinations in rheumatoid arthritis: a formal overview
49. Radiological assessment of disease progression in rheumatoid arthritis patients from the randomized clinical trial of methotrexate, oral gold or combination (abstract)
50. Low‐dose methotrexate compared with auranofin in adult rheumatoid arthritis: a thirty‐six‐week, double‐blind trial